Excretion of over 95% of ... pharmacodynamic properties of a parent drug and its active or inactive metabolites are greatly affected in patients with kidney disease and its resulting uremia.

Buying Regulus ties neatly into Novartis' push into kidney disease therapies, with a portfolio that includes a trio of drugs to treat IgA nephropathy (IgAN) – two of which are already FDA ...

AstraZeneca has licensed in an antisense drug from Ionis Pharmaceuticals to treat kidney disease in a deal worth up to $330 million. Antisense drugs contain non-coding strands of mRNA that block ...

Future Cardiol. 2012;8(5):707-728. These data come from reports of ototoxicity of 6.4% with furosemide compared with 1 and <1% for bumetanide and torsemide, respectively. [38] Acute kidney failure ...